Microsoft says AI agents need their own permissions.

Microsoft says it is expanding Project Perception to manage AI agents inside companies. Each agent would get only the access its current task requires.

Read the full story →Listen to the edition

Microsoft Security ↗Microsoft ↗

Listen to this edition

Prefer audio? The briefing has chapters and a full transcript.

Follow on Apple Podcasts Follow on Spotify Transcript All episodes →

The briefing

The rest of the morning

4 more stories

Robotics and workWarm

Dream Labs offers robot-control software from $3 an hour

Dream Labs announced Dream-1 on October 19. The company offers the robot-control service from $3 an hour and says it can operate unfamiliar two-armed robots with parallel grippers. It also announced $90 million in seed funding. Its Python client is publicly available.

Dream-1 remains a research beta. The company says its performance varies across robots, and it has not validated the model for safety-critical use. Selected demonstrations do not show that the system can work reliably for a full shift.

Dream Labs ↗Dream Labs on PyPI ↗

Read article →

Courts and copyrightWarm

Canadian publishers say Anthropic trained Claude on their journalism

The Canadian Press reported on October 19 that Postmedia, Torstar, The Globe and Mail, and The Canadian Press are suing Anthropic in Ontario. They allege the company used their journalism to develop Claude without a valid licence. The lawsuit was filed on October 6, not on the report date.

The allegations have not been proven in court. The Canadian Press is both a plaintiff and the reporting source. Its report says Anthropic did not immediately respond to a request for comment.

The Canadian Press, via Yahoo Finance ↗

Read article →

Medicine and researchWarm

Tempus reports AI study to help choose lung cancer biomarker tests

Tempus announced an analysis of 60,459 advanced non-small cell lung cancer cases across 56,969 patients on October 19. The company says its image-based panel exceeded 80% sensitivity for each of 12 biomarkers. The work is part of a collaboration with Pfizer.

These are company-reported research results. The panel is still in development and does not replace established molecular or immunohistochemistry tests. Sensitivity alone does not show how many positive predictions are wrong or whether patients receive better care.

Tempus AI ↗

Read article →

Models and evaluationWarm

Preprint tests whether tools improve visual AI

An October 19 preprint introduces OpenVLHarness. The software lets visual AI models call tools while keeping images, data, and web references available during a task. The authors report gains of 9.7 to 12.6 points over matched models without tools, across 22 benchmarks and eight models.

These are the authors' results from a preprint, not an independent reproduction. The reported gains describe the tested benchmarks. They do not establish the reliability or total operating cost of a deployed service.

Yu Zhou and coauthors, arXiv ↗

Read article →

The watchlist

Signals that could change the read

Release documentation, expiring authority and attempts to bypass the supervisor.

Repeated tasks with failed attempts and human interventions counted.

Anthropic's response and court decisions on the publishers' claims.

External results, false positives and changes in follow-up testing.

Across the desks Capability needs limits

Agent permissions, robot reliability and medical predictions each need a test tied to the job.

Agent accessSeparate permissionsMicrosoft says each agent will get only the access its current task requires.

RoboticsA public research betaDream-1's hourly price does not settle what hardware and human interventions will cost.

CopyrightAn Ontario disputeThe publishers' allegations have not been proven.

MedicineChoose the next testTempus says its panel cannot replace established biomarker tests.

Editorial direction, not a financial index. Each signal is tied to this edition’s reporting.

Edition validated · 5 stories · 7 unique sources

About HotTea & our sources →